Skip to main content
Clinical Trials/NL-OMON55997
NL-OMON55997
Recruiting
Not Applicable

on-inferiority of Angiography-derived Physiology Guidance Versus Usual Care in an All-comers PCI Population Treated With Unrestricted Use of the Healing-Targeted Supreme (HT Supreme) Drug-eluting Stent and P2Y12 Inhibitor Monotherapy After 1-month of Dual-antiplatelet Therapy: the PIONEER IV trial - PIONEER-IV Study

niversity of Galway-Prof.James Livesey (Vice President of Research)0 sites595 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Coronary artery disease
Sponsor
niversity of Galway-Prof.James Livesey (Vice President of Research)
Enrollment
595
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Interventional

Investigators

Sponsor
niversity of Galway-Prof.James Livesey (Vice President of Research)

Eligibility Criteria

Inclusion Criteria

  • 1\. Male or female patient \>\=18 years of age;
  • 2\. Patient has chronic stable angina, acute coronary syndromes or silent
  • 3\. Presence of one or more coronary artery stenoses of \>\=50% (by visual
  • assessment) in a native coronary artery (with or without prior stent/other
  • device treatment) or in a saphenous venous or arterial bypass conduit suitable
  • for coronary stent implantation;
  • 4\. The vessel should have a reference vessel diameter of at least 2\.25 mm by
  • visual assessment (no limitation on the number of treated lesions, vessels, or
  • lesion length);
  • 5\. Patient has been informed of the nature of the study and agrees to its

Exclusion Criteria

  • 1\. Patient is a woman who is pregnant or nursing (a pregnancy test must be
  • performed within 7 days prior to the index procedure in women of child\-bearing
  • potential according to local practice);
  • 2\. Known intolerance to cobalt chromium, and medications such as sirolimus,
  • aspirin, heparin, bivalirudin or P2Y12 inhibitors;
  • 3\. Planned major elective surgery requiring discontinuation of (D)APT within 12
  • months of procedure;
  • 4\. Concurrent medical condition with a life expectancy of less than 3 years;
  • 5\. Currently participating in another trial and not yet at its primary
  • 6\. Active pathological bleeding;

Outcomes

Primary Outcomes

Not specified

Similar Trials